Sleep Apnea is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Sleep Apnea have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Sleep Apnea compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sleep Apnea overview
Sleep apnea, a prevalent condition, involves the recurrent interruption and resumption of breathing during sleep. Two main types exist, obstructive and central sleep apnea. Obstructive sleep apnea occurs when the upper airway is frequently blocked, diminishing or halting airflow. Common risk factors include obesity, enlarged tonsils, and hormonal changes. Central sleep apnea results from the brain’s failure to send necessary signals for breathing. Health conditions affecting the brain’s control over airway and chest muscles contribute to this type. Diagnosis involves a sleep study, with treatments including continuous positive air pressure (CPAP) machines and lifestyle adjustments. Surgical intervention may be considered if initial treatments prove ineffective. Untreated sleep apnea can lead to cognitive difficulties and serious health issues.
For a complete picture of PTSR and LoA scores for drugs in Sleep Apnea, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
